Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China

Jing Wu1,2, Chengyu Liu1,2, Fengmei Wang3

  • 1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.

Frontiers in Public Health
|November 22, 2021
PubMed

Insights

Hepatocellular carcinoma (HCC) patients with Urban and Rural Resident Basic Medical Insurance (URRBMI) in China face significantly worse survival rates compared to those with Urban Employee Basic Medical Insurance (UEBMI). This highlights critical healthcare disparities in HCC treatment outcomes.

Area of Science:

  • Oncology
  • Health Services Research
  • Public Health

Background:

  • Health disparities in basic medical insurance coverage for hepatocellular carcinoma (HCC) patients in China remain under-examined.
  • Understanding survival differences based on insurance type is crucial for addressing inequities in cancer care.

Purpose of the Study:

  • To investigate survival disparities among hepatocellular carcinoma (HCC) patients based on their basic medical insurance status in Tianjin, China.
  • To compare outcomes between Urban Employee Basic Medical Insurance (UEBMI) and Urban and Rural Resident Basic Medical Insurance (URRBMI) enrollees.

Main Methods:

  • Retrospective analysis of the Tianjin Basic Medical Insurance claims database (2011-2017).
  • Kaplan-Meier and parametric models assessed overall survival; Cox proportional hazards models adjusted for confounders.
  • Propensity score matching was used for sensitivity analysis.

Main Results:

  • The study included 2,068 HCC patients (1,468 UEBMI, 570 URRBMI).
  • Patients with URRBMI had a median survival of 12.2 months versus 37.8 months for UEBMI.
  • URRBMI patients faced a 72% higher risk of death (adjusted HR: 1.72) compared to UEBMI patients.

Conclusions:

  • Hepatocellular carcinoma (HCC) patients insured under URRBMI exhibit significantly poorer survival outcomes than those under UEBMI.
  • These findings underscore the existence of healthcare disparities linked to basic medical insurance types in China.
  • Further research is needed to elucidate and address these inequities in cancer patient care.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
478
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
340
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K